Loading
The switch-control KIT inhibitor ripretinib lengthened progression-free survival from one to six months and improved survival compared with placebo in gastrointestinal stromal tumours that had failed imatinib, sunitinib and regorafenib.
Phase 3 placebo-controlled trial of 129 patients with advanced GIST after at least three prior kinase inhibitors randomised 2:1 to ripretinib 150 mg daily or placebo with crossover.
Median progression-free survival was 6.3 versus 1.0 months (hazard ratio 0.15) and median overall survival 15.1 versus 6.6 months (hazard ratio 0.36); alopecia, myalgia and hand-foot syndrome were common and mostly low grade.
Ripretinib is the approved fourth-line treatment for GIST and is being tested earlier in mutation-selected patients (INSIGHT).
Shares Ripretinib, Imatinib-resistant GIST.
Shares Ripretinib, Imatinib-resistant GIST.
Shares Ripretinib, Imatinib-resistant GIST.
Shares INVICTUS, Ripretinib.
Shares Ripretinib, Imatinib-resistant GIST.
Shares INVICTUS, Ripretinib, Imatinib-resistant GIST.